Onglyza Lawsuit News: Bernstein Liebhard LLP Comments on Exclusion of Onglyza from Express Scripts 2016 Formulary

August 13, 2015 - Concerns that Onglyza (http://www.onglyzalawsuit2015.com/) might be associated with an increased risk of hospitalization for heart failure have prompted Express Scripts to exclude the Type 2 diabetes medication from its 2016 formulary. According to a report published by Medical Marketing & Media on August 3rd, the country's largest pharmacy benefits manager cited the heart failure concerns surrounding the drug, along with the availability of alternative treatments that do not appear to pose a similar risk, as the rationale for excluding Onglyza.

"Express Scripts' decision to drop Onglyza from next year's formulary comes on the heels of a recommendation by FDA medical reviewers that a possible increased risk of heart failure be noted on the drug's label. The formulary exclusion serves as a reminder that Onglzya may be associated with potentially serious complications," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free Onglyza lawsuit reviews to individuals who were diagnosed with heart failure while being treated with this Type 2 diabetes medication.

Onglyza and Heart Failure
Onglyza (saxagliptin) was approved by the U.S. Food & Drug Administration (FDA) in 2009, and belongs to a class of medications known as DPP-4 inhibitors. It is intended to be used in conjunction with diet and exercise to improve glycemic control in adults with Type 2 diabetes.

In 2014, the FDA launched a review of Onglyza, after a clinical trial known as SAVOR suggested that saxagliptin was associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality. On April 14, 2015, the agency's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14-to-1 to recommend that new information regarding a potential association with heart failure be added to the Onglyza label. While the FDA is not required to follow the recommendations of its advisory panels, it usually does so.

Individuals who allegedly developed heart failure due to their use of Onglyza may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. To find out more about filing an Onglyza lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.onglyzalawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author